anle treatment has been well csrnbl1shcJ tor ., long ume. In contrnsc, prevcnung relapse in Crohn's disease remains an important therapeutic challenge anJ should be discussed accordmg to some ti( ll s relevant aspects, the most 1mporrnnc of whH:h 1s the cl1scase's natural hbtory The data collected from l he place ho groups in maintenam;c therapeutic trials are very intercstmg m this respect. Clt111cal rdapscs occur ,lt a rate of 40 to 65% over ,I 12-to 24-month period (1) (2) (3) .
Results of mamtenance treatment mab arc J 1tficult to interpret in patients with 4u1cscent Crohn's disease because the patients arc not homogeneous with respect co their relapse risk. The easiest way tn ,malyze the results and/or straufy the pattt!nts in dm1cal cnals 1s prohably to take mm account rheir predous clinical history. The typl' of remission ts .1bn of great value. Thcrctore, three different clm1cal sccnanos will be d iscussed separately: patients m complete dm1c,1l rem1ss1on, patients clin1cally and 1m1eroscop1c,1lly m remissio n unmediately after surgery ancl patients '" ith a chronic, mildly active Jiscasc. Patients in complete clinical re mission: In pa nents with complete cl1111cal rcm1~~ion, the ,um of treatment o bviously 1~ to m,11ntam a long-stanJmg prcuve J'activite :.au! unc lcgcrc tcn-dam:e en favcur du 5-ASA. 3/Chez le:, malades ,wee une fonne chmniquc moderemt·nt active lorsque la chirur-gic drnt crre cvitcc du fait de :,es consequences mvaltdantes prdvi:,1hles, l'azathiopr111e et/ou la 16-mercaptopurinc constituent les pmdu1ts !cs plus .1pproprics ct lcs plus cff1caccs. L'interet Ju mctho-tn:xate et/ou Jc la cyclo~porint· reste A etablir.
rcmbs1on with a wdl-tt1lcrated and easy-to-rah· drug.
The treatment of the a..:ute phase nf Cmhn's disease may 1nfluenLe , he fur ther clin 1rnl course; thus, rt·miss111n Ill duced by an clenll'ntal du.:t has been sh(iwn to be shllfler than rcmiss,nn in duu:d hy stcnHds (4, 5) . In faLt, sus rained trcarmenr usu,11ly 1, advised.
Miscdlanc(>Us drugs such as oral BCG (6), levam1z(1le 0) or rifampic1n and ethambutol (7) have nnt heen found ltl he effeuin· m clinical rnab.
The most commonly ust'd drugs ,ire cmticostero,ds, and sulphas,1lazim: and ns Jcnvat1vcs. All controlled 1hera peuttc tnals ( 1,8-1 L) hut one ( 2) han· failed co show any hcnetit from e ither low dtlsc steroid or sulphasalazmc (and even 10 char stuJy (2), steroids alone or m cllmhmat1on with sulphasahmne were only effective in patients who rcsponJcd mitially tll treatment ot active disease; these drugs were not sig111fitanth beneficial when used m macttve disease).
It has been suggested that ,ulphasabdnc efficacy was limited hy its side effects and therefore 5-ammosal,cyltc acid (5-ASA) might be useful when used at equivalent or higher dosage. ln accordance w,rh clinical results in acute phases, fl\·c controlled trials ( L 2-L 6) have been conducted tt1 test the effectiveness of 5-ASA as maintenance treatment. The results of these studies arc somewhat contradictory. Two of them (LZ,16) showed neg.itivc results. In hoth gmups, I ht: do~c was low ( Pcntasa [Brocade~ Pharma] I or 2 g per day, respect1vclv) and the rnal was of short duration (four months). In the first (L2), tlw number of patients mduded was only 46. Despite a greater number of patients ( 101 m each group) and a higher dose ( Pentasa 3 g per/Jay) m I he seconJ study ( 16) , the cumulauvc per centage of relapses over 18 months was the same (29%) m the 5-ASA and the placebo groups, hut the durauon nf rl'm1ss1on hdorl' l'ntry w.is nor r,1ken mto ,Knlunt. The thrL'l' orher trials found results in favour tlf 5-ASA.
In an 111tl'rnat1onal muluu:nrn .. trial ( I 3) (209 p,nicnts), the c:.umulauve pl'rCL'ntage of relapses llVer 12 mtmths was 22.2°0 on l'la\'ers,tl (Sm,chKlme hench) (1 5 g per day) ,·ersus 42.tNn on placeho (P<0.05). with the J,ffcrt·ncc more "1gmf,canr 111 partents with deal disease location ( L 3 ). In rhe FrenLh tnal condut.tcd hy the Groupe d'Etudc Thcrapl'UtllJUes lks Affectllll1S lntl,unmatoires du tuht· d,gcstif (C,ETAIL1) (14) . 161 pat1enb were mduJed ma controlled trial of Pentas,1 ( 2 g per day)
\'ersus placebo ti,·er two years. They were stratified into two strata, presumed to hm c a different relapse risk: a low relapse risk ~tratum (LRRS) h>r patients 111 remtss1on from threl' to 24 months and a high rcl,1pse risk stratum (HRRS) for patients 111 rcm1s-s1on for less than three months. L1fetahlc analysis showed no s1g111f1Lant difference hctween treatment groups m the LRRS, but nnted a s1g111hcant J1f-fl'n~ncc in the HRRS ( P<0.00 3); in this ~tratum, the LUmu larivc percentage of relapse in the Pentasa group was 28 and 5 5 at one and two years, resp,xti\ cly versus 68 and 71 m the placeho group. This d1ftcrence between the two strata was not confirmed by the Italian study ( 15 ) ; 111 that trial, Asarnl (G1uliarn and Bracco) (2.4 g per day) w.ts significantly better than placebo in a group of patienrs in remission for more than three months; the cumulative relapse r,1tes were 34% versus 55°0, respectively, m 12 months (P= 0.02). Patients with chronic, mildly active disease: Patients with chrome milJly active disease arc usually stero,d-Je. pendent, bur dcspue steroid therapy they arc not totally symptom-free, and they relapse as soon as steroids arc dl'c rcased below the threshold ot stermd dependence.
If the level of steroid dependence " low (about LO mg per day), n is likely acceptahle to 01ntmue the same dost., especially if the patient has only a few symptoms. On the contrary, if 1t 1s higher than LO to 15 mg per day, the aim of treatment is nor only to achieve a complete rcnussion, but also to allow steroid sparing and/or weaning.
Bowel rest has heen proven to he effective either as total parenteral nutrition or as a total e lemental Jiet, but the results are often short-lived (21, 22) .
LymphlKyte aphercs1s remam.s controversial. It has been suggested to be of great promise 111 prcl,mmary uncontml-le<l stu<lies (23 ) , b u t in o n e controlle<l Lrial it <lid not prevent early relapse (24 ) . lmmunosuppressants have probably their best indication in steroid-dependent patients, when anticipated consequences of su rgery, such as extensive small bowel resection resulting in severe short bowel syndrome or proctocolcccomy with permanent ileostomy, arc like ly to be disabling.
Methotrcxatc is likely Lo he a useful drug (25) but there is no controlled tria l of its efficacy and cyclnsoprine has no proven efficacy as maintenance treatment (26, 27) . So the most often used immunosuppressant d r ugs are aza-
